NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
25.84
Dollar change
+0.08
Percentage change
0.31
%
IndexRUT P/E- EPS (ttm)-9.53 Insider Own3.59% Shs Outstand12.41M Perf Week170.86%
Market Cap320.59M Forward P/E- EPS next Y-12.11 Insider Trans-16.66% Shs Float11.96M Perf Month132.98%
Enterprise Value288.62M PEG- EPS next Q-2.92 Inst Own- Short Float4.98% Perf Quarter133.33%
Income-133.04M P/S3.67 EPS this Y-19.62% Inst Trans- Short Ratio0.42 Perf Half Y89.76%
Sales87.25M P/B23.34 EPS next Y-16.41% ROA-40.79% Short Interest0.60M Perf YTD85.23%
Book/sh1.11 P/C1.47 EPS next 5Y-16.75% ROE-189.46% 52W High37.38 -30.87% Perf Year58.77%
Cash/sh17.62 P/FCF- EPS past 3/5Y41.29% 25.49% ROIC-74.51% 52W Low6.48 298.77% Perf 3Y-58.59%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-1.15% -3.00% Gross Margin74.12% Volatility35.92% 20.12% Perf 5Y-92.50%
Dividend TTM- EV/Sales3.31 EPS Y/Y TTM31.00% Oper. Margin-160.27% ATR (14)3.53 Perf 10Y-86.19%
Dividend Ex-Date- Quick Ratio3.24 Sales Y/Y TTM-3.24% Profit Margin-152.49% RSI (14)72.93 Recom1.75
Dividend Gr. 3/5Y- - Current Ratio3.24 EPS Q/Q-27.65% SMA2083.90% Beta0.89 Target Price90.67
Payout- Debt/Eq13.59 Sales Q/Q-51.66% SMA50118.07% Rel Volume1.70 Prev Close25.76
Employees61 LT Debt/Eq12.00 EarningsMay 08 AMC SMA20080.13% Avg Volume1.43M Price25.84
IPOMay 03, 1994 Option/ShortYes / Yes EPS/Sales Surpr.-40.39% -31.87% Trades Volume2,431,935 Change0.31%
Date Action Analyst Rating Change Price Target Change
Jun-24-25Reiterated H.C. Wainwright Buy $6.50 → $120
Jun-24-25Reiterated BTIG Research Buy $60 → $100
Apr-11-25Upgrade Jefferies Hold → Buy $2
Mar-14-25Upgrade Oppenheimer Perform → Outperform $6
Jan-08-25Initiated B. Riley Securities Buy $4
Dec-10-24Initiated H.C. Wainwright Buy $6.50
Nov-04-24Initiated Piper Sandler Overweight $7
Sep-30-24Resumed BTIG Research Buy $4
Jun-28-24Initiated Rodman & Renshaw Buy $2
Nov-20-23Resumed JP Morgan Underweight
Jun-30-25 04:02PM
02:21PM
Jun-28-25 08:15AM
Jun-25-25 06:45PM
12:20PM
11:30AM Loading…
11:30AM
Jun-24-25 04:23PM
10:54AM
10:40AM
09:07AM
07:30AM
Jun-23-25 04:30PM
May-13-25 05:00PM
May-09-25 02:29PM
09:08AM
03:46AM Loading…
03:46AM
May-08-25 06:25PM
05:19PM
04:15PM
May-07-25 05:20PM
May-01-25 06:00PM
10:01AM
Apr-11-25 02:29PM
11:30AM
Mar-22-25 06:57PM
Mar-20-25 06:00PM
Mar-14-25 07:33AM
Mar-13-25 12:06PM
03:09AM
Mar-12-25 08:30PM
07:00PM Loading…
07:00PM
06:12PM
04:15PM
Mar-05-25 06:00PM
Feb-27-25 10:59AM
Feb-26-25 07:00AM
Feb-24-25 07:00AM
07:00AM
Feb-10-25 07:00AM
Feb-07-25 09:35AM
Jan-31-25 09:55AM
Jan-10-25 07:00AM
Jan-07-25 09:24AM
Dec-07-24 12:00PM
Nov-18-24 03:30PM
Nov-08-24 02:30AM
Nov-07-24 05:40PM
04:36PM
04:15PM
10:15AM
Nov-06-24 06:00PM
Nov-05-24 10:34AM
Nov-04-24 01:44PM
08:30AM
Oct-31-24 06:00PM
Oct-29-24 09:00AM
Oct-17-24 12:07PM
Sep-25-24 03:30AM
Sep-03-24 09:00AM
Aug-13-24 12:00PM
Aug-09-24 10:58AM
Aug-08-24 05:55PM
04:49PM
04:15PM
Aug-01-24 06:00PM
Jun-12-24 09:30AM
May-30-24 06:00PM
May-10-24 04:41PM
03:14PM
11:33AM
10:35AM
May-09-24 05:39PM
04:15PM
May-02-24 06:00PM
Apr-03-24 11:30AM
Mar-25-24 10:00AM
Mar-22-24 02:00PM
Mar-06-24 12:33PM
Mar-05-24 10:07AM
09:13AM
09:00AM
07:19AM
Mar-04-24 05:30PM
04:51PM
04:42PM
04:15PM
08:30AM
Feb-27-24 06:00PM
Feb-26-24 06:00PM
Feb-20-24 10:00AM
Jan-03-24 06:00PM
Dec-11-23 06:00PM
Dec-07-23 11:31AM
Nov-09-23 08:39AM
Nov-08-23 11:47AM
Nov-07-23 05:28PM
04:15PM
Oct-31-23 06:00PM
Oct-26-23 10:02AM
Oct-23-23 10:08AM
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zalevsky JonathanChief R&D OfficerMay 19 '25Sale0.6710,7127,177305,892May 21 08:08 PM
Wilson Mark AndrewChief Legal OfficerMay 19 '25Sale0.679,9966,697314,296May 21 08:07 PM
ROBIN HOWARD WPresident & CEOMay 19 '25Sale0.6723,20815,5491,063,693May 21 08:07 PM
Zalevsky JonathanOfficerMay 19 '25Proposed Sale0.6710,7127,191May 19 03:49 PM
Wilson Mark AndrewOfficerMay 19 '25Proposed Sale0.679,9966,710May 19 03:44 PM
ROBIN HOWARD WOfficerMay 19 '25Proposed Sale0.6723,20815,580May 19 03:40 PM
Zalevsky JonathanChief R&D OfficerFeb 19 '25Sale1.0110,30010,403316,604Feb 21 06:07 PM
Wilson Mark AndrewChief Legal OfficerFeb 19 '25Sale1.0111,04011,150324,292Feb 21 06:06 PM
ROBIN HOWARD WPresident & CEOFeb 19 '25Sale1.0123,77424,0121,086,901Feb 21 06:04 PM
Wilson Mark AndrewOfficerFeb 19 '25Proposed Sale1.0111,04011,137Feb 19 03:27 PM
ROBIN HOWARD WOfficerFeb 19 '25Proposed Sale1.0123,77423,983Feb 19 03:21 PM
Zalevsky JonathanOfficerFeb 19 '25Proposed Sale1.0110,30010,391Feb 19 03:18 PM
Wilson Mark AndrewChief Legal OfficerDec 23 '24Sale0.9033,40230,062351,892Dec 26 07:04 PM
Wilson Mark AndrewChief Legal OfficerDec 24 '24Sale0.8916,56014,738335,332Dec 26 07:04 PM
Wilson Mark AndrewOfficerDec 24 '24Proposed Sale0.8916,56014,801Dec 26 09:35 AM
Wilson Mark AndrewOfficerDec 23 '24Proposed Sale0.9033,40229,898Dec 23 03:21 PM
Zalevsky JonathanChief R&D OfficerDec 19 '24Sale0.9451,11548,048326,904Dec 20 08:33 PM
ROBIN HOWARD WPresident & CEODec 18 '24Sale0.9985,03584,1851,110,675Dec 19 09:08 PM
ROBIN HOWARD WPresident & CEODec 17 '24Sale1.0146,99547,4651,195,710Dec 19 09:08 PM
Zalevsky JonathanOfficerDec 19 '24Proposed Sale0.9451,11548,063Dec 19 03:12 PM
ROBIN HOWARD WOfficerDec 18 '24Proposed Sale0.9985,03584,244Dec 18 04:17 PM
ROBIN HOWARD WOfficerDec 17 '24Proposed Sale1.0146,99547,338Dec 17 03:29 PM
Zalevsky JonathanChief R&D OfficerNov 19 '24Sale1.017,7857,863243,019Nov 20 08:37 PM
Wilson Mark AndrewChief Legal OfficerNov 19 '24Sale1.016,4076,471218,856Nov 20 08:36 PM
ROBIN HOWARD WPresident & CEONov 19 '24Sale1.0116,27816,441832,080Nov 20 08:36 PM
Zalevsky JonathanOfficerNov 19 '24Proposed Sale1.017,7857,878Nov 19 04:10 PM
Wilson Mark AndrewOfficerNov 19 '24Proposed Sale1.016,4076,483Nov 19 03:28 PM
ROBIN HOWARD WOfficerNov 19 '24Proposed Sale1.0116,27816,472Nov 19 03:17 PM
Zalevsky JonathanChief R&D OfficerAug 19 '24Sale1.286,8668,788250,804Aug 20 09:15 PM
Wilson Mark AndrewChief Legal OfficerAug 19 '24Sale1.285,6517,233225,263Aug 20 09:15 PM
ROBIN HOWARD WPresident & CEOAug 19 '24Sale1.2814,88119,048848,358Aug 20 09:14 PM
Wilson Mark AndrewOfficerAug 19 '24Proposed Sale1.285,6517,211Aug 19 04:13 PM
ROBIN HOWARD WOfficerAug 19 '24Proposed Sale1.2814,88118,990Aug 19 04:03 PM
Zalevsky JonathanOfficerAug 19 '24Proposed Sale1.286,8668,762Aug 19 03:45 PM